Rexin G is a tumor-targeted genetic medication used in the treatment of patients with metastatic breast cancer. It is a peptide-based drug that binds to and inhibits the activity of tumor-associated protein kinases.  Rexin G is approved for the treatment of metastatic breast cancer in the United States and Europe. It is also under evaluation for the treatment of other cancers. Rexin G has been shown to be safe and effective in clinical trials. The most common side effects associated with Rexin G therapy are diarrhea, nausea, and vomiting.
